Abstract
Objective:
To assess the frequency of advance care planning (ACP) and associated demographic and clinical factors among women with metastatic breast cancer (MBC).
Methods:
We analyzed secondary data from a longitudinal study of quality of life among women with MBC. Participants (N = 118) were recruited from breast oncology clinics at an NCI-designated comprehensive cancer center. Participants completed surveys assessing demographic and clinical characteristics. Data on ACP completion (yes/no) were abstracted from the electronic medical record. Chi-square or t-tests assessed bivariate relationships between demographic and clinical characteristics and ACP completion. Characteristics that were significantly related (p < 0.01) were entered into a multivariable logistic regression.
Results:
Only 38% (45/118) of participants had completed ACP. In multivariable analyses, older age and greater education were positively associated with ACP completion (ORage = 1.04 [1.01–1.08]; OReducation = 2.32 [1.04–5.20]).
Conclusions:
ACP interventions should target women with MBC who are younger and with lower levels of educational attainment.
Introduction
Advance care planning (ACP) is the process of discussing and recording patient preferences for future medical care. 1 ACP is associated with reduced hospitalizations, increased use of hospice and palliative care, and decreased cost of care at the end of life.2–5 ACP is a key component of the National Comprehensive Cancer Network (NCCN) guidelines for palliative care 6 and is a Centers for Medicare and Medicaid services care quality indicator for all individuals aged 65 and older. 7
However, only 12–34% of patients with advanced cancer have completed ACP.8–11 When ACP does occur, it is often in the last few months of life and/or in the inpatient setting.8,12 This contrasts with NCCN guidelines 6 and patient preferences for ACP to occur early. 13 Thus, improvements in ACP are urgently needed in order to provide quality cancer care.
Understanding which individuals are more or less likely to have completed ACP may guide tailored intervention strategies. The metastatic breast cancer (MBC) population is ideal for addressing this research question, as MBC is typically considered to be incurable, 14 but novel treatment approaches have resulted in significantly increased survival times following MBC diagnosis.15–17 This population can thus provide valuable, novel insight into ACP among those for whom ACP is salient, but are not at the end of life. Leveraging secondary data from an observational study of quality of life among women with MBC,18,19 we aimed to: (1) characterize the frequency of ACP among women with MBC and (2) identify specific subgroups of women with MBC who are less likely to have completed ACP.
Methods
Procedures and participants
We conducted secondary data analyses from a longitudinal study of quality of life among women with MBC.18,19 All procedures were reviewed and approved by the Institutional Review Board at Georgetown University (IRB #00005081).
Participants were recruited between January 2023 and April 2024 from breast medical oncology clinics in Washington, DC, Baltimore, MD, and Hackensack, NJ. Eligibility criteria and recruitment procedures for the parent study have been previously reported.18,19 Briefly, eligible participants were assigned female at birth; age ≥18; diagnosed with MBC; able to speak English or Spanish; and had a working telephone capable of receiving SMS messages and accessing the Internet (due to the design of the parent study). Participants completed a brief baseline survey and four weeks of follow-up surveys. Upon completion of the follow-up period, trained research staff manually reviewed the electronic medical record (EMR) and abstracted key variables of interest during the period between study enrollment and completion or withdrawal (M = 58 days, standard deviation [SD] = 36 days).
Measures
Demographic characteristics
Participants self-reported age, race, ethnicity, education level, partner status, and current caregiving responsibilities.
Comorbidities
We used a simplified comorbidity index based on the Charlson Comorbidity Index.20–22 Participants indicated whether they had been diagnosed with any of 12 health conditions (e.g., heart attack, asthma), and up to two “other” medical conditions. Possible scores were 0 to 14 (higher = more comorbidities).
Health literacy
The BRIEF Health Literacy Screening Tool23,24 includes 4 items rated on a 5-point Likert scale (1 = “never” to 5 = “always”). Total scores range from 4 to 20 (higher = better); scores ≥16 indicate adequate health literacy.
Clinical characteristics
Location of MBC care (Washington, Baltimore, or NJ) and time since MBC diagnosis were abstracted from the EMR.
ACP completion
EMR-documented completion of ACP (yes/no) included: (1) a Medical Orders for Scope of Treatment form, a Medical Order for Life Sustaining Treatment form, or a Physician Orders for Life Sustaining Treatment form; (2) an advance directive or living will; and/or (3) a medical durable power of attorney.
Data analysis
Analyses were conducted with IBM SPSS (version 29). Cases with missing data were removed listwise. Chi-square or t-tests (as appropriate) assessed bivariate relationships between demographic and clinical characteristics and ACP completion. Characteristics that were significantly related (p < 0.10) at the bivariate level were subsequently entered into a multivariable logistic regression model. Goodness of fit was evaluated by Hosmer and Lemeshow’s test. 25
Results
Of 125 consenting patients, 118 (94%) completed the baseline survey and were included in these analyses (see Table 1). About one-third (n = 45, 38%) had completed ACP. In bivariate analyses (see Table 2), ACP completion was significantly associated with age (p = 0.037), such that participants who had completed ACP were older on average (M = 61 years) than participants who had not completed ACP (M = 56 years). ACP completion was also marginally associated with education (p = 0.089), such that participants with a Bachelor’s degree or greater were more likely to have completed ACP (45%) than those with less than a Bachelor’s degree (29%).
Participant Demographic and Clinical Characteristics, Overall, and by ACP Completion
Bold values indicate p-values less than 0.1.
p Value for chi-square test, Fisher’s exact test, or student’s t-test, as appropriate.
As participants could select more than one response, it does not total 100%.
ACP, advance care planning.
Results of Multivariable Logistic Regression Model Examining Demographic and Clinical Characteristics Associated with ACP Completion (N = 118)
Age and education were entered in a multivariable logistic regression model with ACP completion specified as the dependent variable. Both age and education remained significant in the multivariable analyses. Participants were 4% more likely to have completed ACP for each additional year of age (Odds Ratio = 1.04, 95% Confidence Interval: 1.01–1.08). Compared to participants with less than a Bachelor’s degree, participants with a Bachelor’s degree or greater were more than twice as likely to have completed ACP (Odds Ratio = 2.32, 95% Confidence Interval: 1.04–5.20). The final multivariable model demonstrated adequate goodness of fit (χ2=5.55, p = 0.698).
Discussion
This study extends the prior literature by assessing the frequency of EMR-documented ACP and associated demographic and clinical factors among women with MBC. Rates of ACP among women with MBC were similar to those previously reported for patients with advanced cancer8–11 and suggest room for improvement.
Participants who were younger and with lower levels of education were less likely to have EMR-documented ACP. While the relationship between education level and ACP completion is well-documented in other populations,26–28 the prior literature on age and ACP is less clear. While some studies show that ACP engagement increases with age,26,29–32 Prater and colleagues 33 found that odds of having documented ACP decreased with age, when controlling for prognosis. These conflicting results may suggest a more complex, nonlinear relationship between age and ACP completion. In the context of MBC, our results suggest additional outreach may be needed to encourage ACP among younger patients and those with lower levels of education. Tools and educational materials tailored to life stages and in plain language may have particular utility. 34
Prior research demonstrates that non-Hispanic White cancer patients are more likely to have completed ACP than Black and Latino cancer patients,35,36 but we did not observe differences in ACP completion by participant race or ethnicity. While we enrolled a relatively diverse sample in terms of race and ethnicity, they were homogenous in other ways: all were receiving care at an NCI-designated comprehensive cancer center, most had a college education or greater, and nearly all had adequate levels of health literacy. Given the complex relationships among race, ethnicity, socioeconomic status, and health care access in the United States, 37 a larger and/or more socioeconomically diverse sample may be needed in order to detect disparities in ACP completion. Additionally, these are secondary data analyses, and the parent study was not specifically designed to examine ACP completion among women with MBC. Thus, it is possible that we were underpowered to detect differences in ACP completion by race and ethnicity. Additional larger studies, specifically designed to examine ACP, are needed to fully characterize the landscape of ACP among women with MBC.
ACP completion is a complex, multifaceted process involving multiple stakeholders. While our study design only allowed us to examine patient-level factors that may be associated with ACP completion, barriers also exist at the provider, organizational, and health care system levels. For example, fragmented communication about ACP, discomfort discussing ACP, staffing limitations/turnover, time burden for ACP, competing clinical demands, and unclear division of tasks related to ACP have all been identified as barriers to ACP completion.38,39 Interventions aiming to increase rates of ACP completion must therefore act at multiple levels of influence, including the patient, provider, organization, and health care system. 3 The Consolidated Framework for Implementation Research 40 is widely used to identify factors that affect the implementation of new practices or interventions. It organizes these factors across five key domains (intervention characteristics, outer setting, inner setting, characteristics of individuals, and process), providing a common language and structure for implementation assessment and planning. Using this framework to understand the multiple levels of influence on ACP completion would support the development of targeted interventions that address not only individual but also health care system or community level influences.
Study Limitations
First, the use of EMR data is an imperfect way to assess ACP.41,42 We did not capture ACP data from outside of our system, and it is possible that participants had completed ACP elsewhere. Future studies might supplement EMR data with patient-reported data to fully capture ACP across clinical care settings. Second, data were drawn from a study on quality of life in MBC. Participants thus reflect a subgroup that was able and willing to participate in this study. The specific eligibility characteristics of the parent study (i.e., smartphone ownership) may have further limited our sample to individuals with higher socioeconomic status or levels of digital literacy. Finally, most participants in this study were non-Hispanic White and highly educated. Results may not generalize to the broader, socioeconomically or racially/ethnically diverse population of people with MBC.43,44
Conclusions
Women with MBC who are younger and with lower levels of educational attainment may benefit from interventions to increase ACP completion. Furthermore, levels of ACP completion overall are low due to complex individual and system-level issues that need to be further assessed and addressed in order to complete this evidence-based practice more broadly across MBC patients.
Authors’ Contributions
All authors contributed to the study conception and design. Material preparation and data collection were performed by J.S., M.V.-S., A.B., A. M., H.K., and J.D.R. Data analysis was performed by C.C.C. and J.S. The first draft of the article was written by C.C.C. All the authors commented on subsequent versions of the article. All the authors read and approved the final article.
Footnotes
Acknowledgment
The authors would like to thank Anastacia Wahl for her assistance with EMR review.
Author Disclosure Statement
C.C.C. has received research support (to institution) from Pfizer. C.I. has participated in consulting activities for which she has received honoraria from AstraZeneca, Genentech, Seattle Genetics, Pfizer, Gilead, and Merck; royalties from Wolters Kluwer (UptoDate) and McGraw Hill (Goodman and Gillman); and research support (to institution) from Tesaro/GSK, Seattle Genetics, Pfizer, AztraZeneca, Bristol Myers Squibb, Genentech, and Novartis. S.C.O’N. has received research support (to institution) from Pfizer and Gilead Sciences. No other authors have competing interests to disclose.
Funding Information
This work was supported by the National Cancer Institute (R03 CA273489, PI: C.C.C.; T32CA261787, PI: S.C.O’N., Adams-Campbell, Schwartz; P30 CA051008, PI: Weiner). The content presented here is solely the responsibility of the authors and does not represent the official views of the National Cancer Institute.
